mRNA Technology Newsletter
Issue #15December 15, 20257 studies

Simple chemical tweak redirects mRNA vaccines from liver to lungs and spleen

This week brought major advances in making mRNA vaccines smarter about where they go in the bodyβ€”plus promising results for everything from Alzheimer's to parasitic diseases.

🎯 One atom swap redirects mRNA vaccines to different organs

  • Researchers replaced a single nitrogen atom with sulfur in the widely-used vaccine lipid ALC-0315, completely changing where mRNA vaccines go in the bodyβ€”from liver to lungs

  • The modified lipid (S-ALC-0315) mixed with the original at a 1:2 ratio created vaccines that specifically targeted the spleen instead

  • Spleen-targeting vaccines generated stronger anti-tumor immune responses and produced significant anti-cancer effects in two different tumor models while maintaining safety

Why it matters: This atomic-level modification offers a simple way to reprogram existing approved vaccine components for different diseases without starting from scratch with new safety testing.

πŸ₯‡ Top 1% journal πŸ”— Advanced materials (Deerfield Beach, Fla.) Journal Article πŸ—“οΈ Dec 12

Key Findings

🧠 CRISPR gene editing clears Alzheimer's plaques in mouse brains

  • Scientists used lipid nanoparticles to deliver CRISPR tools that boost Mt3 protein production in brain support cells (astrocytes)

  • The enhanced Mt3 expression significantly increased astrocytes' ability to engulf and clear amyloid-beta plaques

  • Direct brain injection of the CRISPR system led to a marked reduction in plaque accumulation in Alzheimer's disease mice

πŸ’‘ This approach could offer a way to enhance the brain's natural cleanup mechanisms for Alzheimer's disease.
πŸ₯ˆ Top 2% journal πŸ”— Advanced science (Weinheim, Baden-Wurttemberg, Germany) Journal Article πŸ—“οΈ Dec 12

🦠 mRNA vaccines show promise against neglected parasitic diseases

  • Researchers outlined how mRNA vaccine technology could tackle parasitic infections that affect vulnerable populations worldwide

  • The adaptable platform can target complex parasite life cycles and effectively modulate immune responses

  • Key challenges include cold-chain storage requirements, manufacturing scale-up, and community acceptance in resource-limited settings

πŸ’‘ mRNA technology may extend beyond COVID-19 to address diseases that disproportionately affect the world's most vulnerable populations.
πŸ₯‰ Top 5% journal πŸ”— Journal of nanobiotechnology Review πŸ—“οΈ Dec 13

πŸ’‰ Virus-like particle mRNA vaccines outperform standard COVID shots

  • mRNA vaccines encoding virus-like particles (mRNA-VLPs) generated stronger neutralizing antibody responses across multiple COVID variants compared to conventional spike protein vaccines

  • In non-human primates, elevated antibody levels lasted at least six months

  • Even low doses of mRNA-VLP vaccines provided complete protection in hamsters, matching the performance of high-dose standard vaccines

πŸ’‘ This platform could significantly strengthen vaccine effectiveness against evolving SARS-CoV-2 variants.
πŸ₯‰ Top 5% journal πŸ”— NPJ vaccines Journal Article πŸ—“οΈ Dec 13

🫁 Targeted lung delivery enhances cancer immunotherapy

  • Mannose-modified lipid nanoparticles delivered both silencing RNA and immune-stimulating mRNA specifically to lung macrophages

  • The combination therapy reprogrammed tumor-promoting immune cells into cancer-fighting ones

  • When combined with checkpoint inhibitors, the treatment significantly boosted anti-tumor responses in lung cancer and lung metastasis models

πŸ’‘ Precise cell-targeting could convert immunotherapy non-responders into long-term survivors.
πŸ₯‰ Top 5% journal πŸ”— Journal of controlled release : official journal of the Controlled Release Society Journal Article πŸ—“οΈ Dec 10

🩸 mRNA produces clotting factor for hemophilia treatment

  • Lipid nanoparticles carrying mRNA for the MG1113 antibody (which targets a clotting inhibitor) enabled sustained antibody production in mice and rabbits

  • The mRNA approach provided longer-lasting effects and more efficient plasma protein suppression compared to direct antibody injection

  • This factor-independent strategy could offer prolonged treatment with simplified manufacturing

πŸ’‘ mRNA systems may advance next-generation treatments for bleeding disorders beyond traditional factor replacement.

πŸ”¬ Getting COVID and flu shots together doesn't weaken immune response

  • A randomized trial of 335 people found no reduction in COVID vaccine effectiveness when given simultaneously with flu shots

  • Antibody levels against the original virus strain and BA.4/5 variant were nearly identical between simultaneous and sequential vaccination groups

  • Post-vaccination antibody titers were 4,357 vs 4,492 for simultaneous vs sequential groups (no significant difference)

πŸ’‘ People can safely receive both vaccines at the same appointment without compromising protection.
Top 20% journal πŸ”— Vaccine Journal Article πŸ—“οΈ Dec 11

Implications

These studies show mRNA technology is rapidly expanding beyond COVID vaccines into precision medicine. The ability to redirect vaccines to specific organs and cell types, combined with growing applications in cancer, genetic diseases, and neglected infections, suggests we're entering an era where mRNA can be programmed like software to target exactly where therapeutic action is needed.

Studies in this issue

Primary sources used for this newsletter.

  1. Changing mRNA delivery targets by replacing nitrogen with sulfur in charged lipids
    main storyAdvanced materials (Deerfield Beach, Fla.)2025-12-12PMID 41386688
  2. mRNA Vaccines and Treatments for Parasitic Infections: A Complete Overview
    key findingJournal of nanobiotechnology2025-12-13PMID 41390653
  3. Boosting a Protective Protein in Brain Support Cells May Improve Clearing of Alzheimer's Amyloid in Mice
    key findingAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025-12-12PMID 41387343
  4. Lung immune cell-targeted RNA delivery using special lipid particles may improve lung cancer immunotherapy
    key findingJournal of controlled release : official journal of the Controlled Release Society2025-12-10PMID 41371503
  5. Using mRNA to produce MG1113 antibody inside the body as a possible treatment for hemophilia
    key findingJournal of controlled release : official journal of the Controlled Release Society2025-12-09PMID 41365435